Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer
This study has been completed.
Sponsor:
Sarah Cannon Research Institute
Collaborators:
Ortho Biotech, Inc.
Aventis Pharmaceuticals
Information provided by:
Sarah Cannon Research Institute
ClinicalTrials.gov Identifier:
NCT00193037
First received: September 12, 2005
Last updated: May 2, 2011
Last verified: May 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | November 2009 |
| Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |